Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of Oralgen Grass Pollen in allergic rhinoconjunctivitis (AB0602 follow-up)
2007-002477-31Phase 2Completed
- Sponsor
- Artu Biologicals
- Start
- May 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Oralgen Grass Pollen in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Artu Biologicals. Primary endpoint: Rhinoconjunctivitis Total Symptom Score. Started May 2007; status: completed.
02
Drugs
Oralgen Grass Pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2007-002477-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002477-31.